Sessa Capital IM's Q3 and Q4 2022 13F Holdings Comparison Reveals Interesting Changes in Portfolio

Sessa Capital IM, L.P. is a well-known investment management firm that specializes in equity investment strategies. The firm recently released a CSV showing its Q3 2022 and Q4 2022 13F holdings comparison. The CSV summarizes the changes in holdings of the fund during this period.

Let's take a closer look at some of the changes in the fund's holdings during Q3 2022 and Q4 2022.

One of the largest changes in the fund's portfolio was the decrease in holdings of WARNER BROS DISCOVERY INC (WBD). The fund held 22,254,967 shares of WBD in Q3 2022, but only held 23,450,633 shares in Q4 2022. This translates to a decrease in value of approximately 13.1%.

On the other hand, the fund increased its holdings in EQUITABLE HLDGS INC (EQH) from Q3 2022 to Q4 2022. In Q3 2022, the fund held 6,931,147 shares of EQH, while it held the same number of shares in Q4 2022. However, the value of these holdings increased by 8.9%.

Another interesting change in the fund's holdings was the significant increase in value of its holdings in PROVENTION BIO INC (PRVB). The fund held 14,879,023 shares of PRVB in both Q3 and Q4 2022. However, the value of these shares increased by 134.9% in Q4 2022.

Similarly, the fund's holdings in INTERNATIONAL FLAVORS&FRAGRA (IFF) increased significantly from Q3 2022 to Q4 2022. The fund held 694,043 shares of IFF in Q3 2022, but held 1,349,675 shares in Q4 2022. This translates to an increase in value of 124.5%.

One of the most notable changes in the fund's holdings was its acquisition of 1,480,171 shares in US FOODS HLDG CORP (USFD) in Q4 2022. The fund did not hold any shares in USFD in Q3 2022, but holds nearly 1.5 million shares in Q4 2022.

The fund also acquired 400,000 shares in META PLATFORMS INC (META) and 1,803,191 shares in ALLY FINL INC (ALLY) in Q4 2022. Similarly, the fund acquired 2,313,053 shares in NEWS CORP NEW (NWSA) and 1,980,753 shares in JBG SMITH PPTYS (JBGS) during this period.

The fund also saw a decrease in holdings of XERIS BIOPHARMA HOLDINGS INC, APELLIS PHARMACEUTICALS INC, and RELAY THERAPEUTICS INC during Q4 2022.

Overall, the changes in the fund's holdings highlight its investment strategy and pattern of investment. By analyzing the holdings and value of different companies, investors can make better-informed decisions about potential investment opportunities. It is important to note that the changes in holdings may not always reflect a company's performance, and investors should conduct their own research before making any investment decisions.